Anxiety Sensitivity Clinical Trial
Official title:
Does a Values Rationale Increase Willingness to Tolerate Distress in Interoceptive Exposure: Examination of a One-Session Randomized Clinical Trial
NCT number | NCT04259190 |
Other study ID # | 20-024 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | June 1, 2022 |
Est. completion date | August 30, 2022 |
Verified date | June 2020 |
Source | University of Mississippi, Oxford |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the current study is to examine the effect of emphasizing values in the treatment rationale on treatment response, willingness to tolerate distress, and acceptability of a one-session interoceptive exposure intervention for the reduction of anxiety sensitivity. A standard treatment rationale without values emphasis will serve as a control.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | August 30, 2022 |
Est. primary completion date | August 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Score = 23 on the Anxiety Sensitivity Index - 3 (ASI-3) Exclusion Criteria: - Seizures - Hypertension - Heart problems - Current pregnancy - Asthma - Other health conditions exacerbated by intense exercise |
Country | Name | City | State |
---|---|---|---|
United States | University of Mississippi | University | Mississippi |
Lead Sponsor | Collaborator |
---|---|
Gina Boullion |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Willingness to tolerate distress | Willingness to tolerate distress will be assessed by identifying the activity item on the Albany Panic and Phobia Questionnaire (APPQ) - Agoraphobia subscale to which the participant responded with the highest score indicating most fear. The participant will then be asked, "How willing would you be to do [most feared activity] next week?" Responses will range from 0% to 100%. | change from pre-intervention to immediately post-intervention | |
Secondary | Straw breathing BAT peak fear ratings | Participants will be asked to engage in hyperventilation via breathing through a cocktail straw for three consecutive minutes pre-intervention. Participants will be asked to rate their peak fear ranging from 0 ("no fear") to 100 ("extreme fear or panic") on a 100-point visual analog scale after each minute. A peak fear rating will be calculated by computing the average of the three ratings. | pre-intervention | |
Secondary | Overbreathing BAT peak fear ratings | Participants will be asked to engage in one last overbreathing task post-intervention to see how long they can overbreathe. After discontinuation, participants will be asked to report their current level of fear ranging from 0 ("no fear") to 100 ("extreme fear or panic") on a 100-point visual analog scale. | immediately post-intervention | |
Secondary | Between trial fear ratings | After each voluntary hyperventilation trial, participants will be asked to provide ratings of their peak fear. Participants will be asked to rate their peak fear during the trial ranging from 0 ("no fear") to 100 ("extreme fear or panic") on a 100-point visual analog scale. | change from pre-intervention to immediately post-intervention | |
Secondary | Anxiety Sensitivity Index - 3 (ASI-3) | The ASI-3 is an 18-item self-report measure of the fear of physiological arousal-related sensations. Scores on the ASI-3 can range from 0 to 72, with higher scores reflecting greater fear of arousal-related symptoms. | change from pre-intervention to immediately post-intervention | |
Secondary | Albany Panic and Phobia Questionnaire (APPQ) | The APPQ is a 27-item self-report measure of the fear of activities often avoided by individuals with agoraphobia and social phobia, and activities that typically produce physical sensations. Scores on the APPQ can range from 0 to 216, with higher scores reflecting higher levels of fear. | change from pre-intervention to immediately post-intervention | |
Secondary | Between trial tolerability ratings | After each voluntary hyperventilation trial, participants will be asked to provide ratings of tolerability of physiological sensations. Participants will be asked to rate the extent they perceived themselves as able to tolerate the physiological sensations during hyperventilation from 0 ("unable to tolerate them at all") to 100 ("completely able to tolerate them") on a 100-point visual analog scale. | change from pre-intervention to immediately post-intervention | |
Secondary | Treatment Acceptability Questionnaire | A three-item self-report questionnaire was administered to participants to assess acceptability of the treatment provided. Participants will rate treatment acceptability, likeability, and aversiveness from "not at all" to "extremely" on a five-point Likert scale. Scores on the Treatment Acceptability Questionnaire can range from 0 to 12, with higher scores reflecting greater acceptability. | immediately post-intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02874417 -
Computerized Psychoeducation for Anxiety Sensitivity
|
N/A | |
Completed |
NCT03917901 -
Computer-Delivered Intervention for Individuals With Obesity and Elevated Anxiety Sensitivity
|
N/A | |
Recruiting |
NCT05383989 -
The UniVenture Program
|
N/A | |
Active, not recruiting |
NCT05416203 -
BEAST: A Pilot Trial
|
N/A | |
Not yet recruiting |
NCT05490199 -
Brief Enhanced Anxiety Sensitivity Treatment
|
N/A | |
Completed |
NCT03128437 -
Anxiety, Mood, and Health Behaviors in Young Adults
|
N/A | |
Completed |
NCT01194765 -
Distance-Based Cognitive-Behavioural Therapy for High Anxiety Sensitivity: A Randomized Controlled Trial
|
N/A | |
Enrolling by invitation |
NCT01201304 -
Comparison of Methods for the Delivery of Interoceptive Exposure
|
Phase 2 | |
Completed |
NCT05458362 -
Brief Enhanced Anxiety Sensitivity Treatment (Group)
|
N/A | |
Enrolling by invitation |
NCT04129866 -
Mobile Interpretation Bias Modification Clinical Trial
|
N/A |